AI-generated analysis. Always verify with the original filing.
Jasper Therapeutics reported Q4 and full year 2025 financial results with net loss of $9.1 million and $75.8 million respectively, cash of $28.7 million, and positive briquilimab data in urticaria and asthma.
Event Type
Disclosure
Mandatory
Variant
8-K
, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 2.02 and Item 9.01 of Current Report on Form 8-K and shall not be d
. Financial Statements and Exhibits.** (d) Exhibits. | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press Release, dated March 30, 2026. | | 104 | | C
| Metric | Value | Basis |
|---|---|---|
| Research and development expense | $11.4K | GAAP |
| General and administrative expense | $4.5K | GAAP |
| Net loss | $-9.1K | GAAP |
| Net loss per share | $-0.32 | GAAP |